Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J.F. Belch,
Deborah P.M. Symmons,
The TRACE RA consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Peter Nightingale,
Tags: Full Length Source Type: research
More News: Arthritis | Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Diabetes | Endocrinology | Heart | Heart Attack | Ischemic Stroke | Lipitor | Rheumatoid Arthritis | Rheumatology | Statin Therapy | Stroke | Zivast